# ChipBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chipbio

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.chipbio.cn
- Latest round: Series A (Jul 22, 2025)
- Investors on record: 4

## About

Based in Chengdu, China, ChipBio specializes in the development and manufacturing of innovative biomaterials and implantable medical devices for diverse medical fields.Founded in 2016, Chengdu ChipBio Co., Ltd. focuses on biomedical technologies, particularly in developing advanced biomaterials and medical devices. The company has completed a total of 3 deals, with its most recent deal occurring on July 22, 2025.Chengdu ChipBio Co., Ltd. specializes in the development and manufacturing of advanced biomaterials and implantable medical devices tailored for various medical fields, including medical aesthetics, urology, orthopedics, and oral repair. Their core product offerings include medical-grade collagen, cross-linked yak pericardium, micronized acellular dermal matrix (mADM), small intestinal submucosa (SIS), polycaprolactone (PCL) microspheres, and poly-L-lactic acid (PLLA) microspheres. These products are engineered to address critical healthcare needs by providing solutions for tissue repair, enhancement, and aesthetic applications, leveraging their exceptional biocompatibility. ChipBio serves a diverse client base that includes hospitals, medical practitioners, and cosmetic surgery clinics across various geographical markets, although specific regional sales distributions are not detailed.Chengdu ChipBio Co., Ltd. generates revenue primarily through direct sales of its biomaterials and medical devices to healthcare providers and institutions. The company engages in business-to-business transactions, establishing partnerships with hospitals and clinics that utilize its products in surgical and aesthetic procedures. Transactions are structured on an order basis, where clients place bulk orders for specific biomaterials or medical devices tailored to their operational needs. The pricing structure for these products aligns with industry standards, reflecting the advanced nature of the technologies and materials used. ChipBio’s flagship products, such as the medical-grade collagen and mADM, are central to its revenue streams, given their broad applications in regenerative medicine and surgical interventions.In July 2025, ChipBio raised an undisclosed amount of venture funding from new investor HWealth Capital, Jiaozi Park Investment, and Geuniom Group, along with returning investor Chengdu Venture Capital. The company plans to utilize these funds to support the development of new innovative products aimed at expanding their product lineup. Additionally, ChipBio is targeting expansion into new markets, with a focus on increased presence in Southeast Asia by 2026.

## Funding rounds

- Series A, Jul 22, 2025 — Chengdu Venture Capital, Geuniom Group, HWealth Capital, Jiaozi Park Investment

## Investors

- Chengdu Venture Capital (https://capitalatlas.ai/funds/chengdu-venture-capital) — Series A
- Geuniom Group — Series A
- HWealth Capital (https://capitalatlas.ai/funds/hwealth-capital) — Series A
- Jiaozi Park Investment — Series A